Feb. 3 (UPI) -- Merck said Thursday it sold $952 million of molnupiravir, its coronavirus treatment pill, over the fourth quarter in 2021 and expects to sell up to $6 billion this year.
The drugmaker highlighted its oral treatment with Ridgeback Biotherapeutics in its fourth quarter and 2021 year-end report. The Food and Drug Administration authorized the drug for emergency use in December.